United Health Products Announces Completion of IQVIA Independent Market Assessment for HemoStyp® in Support of Review of Strategic Alternatives


HENDERSON, Nev., May 07, 2019 (GLOBE NEWSWIRE) -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that IQVIA has completed its independent market assessment of certain market opportunities for HemoStyp. This survey used a combination of interviews, market data and product usage reports to create a detailed outlook for HemoStyp’s revenue potential assuming, among other factors, the receipt of FDA approval for Class III surgical applications. The primary purpose of the study is to assist the Company in its previously announced Review of Strategic Alternatives. On April 30th, IQVIA made a formal presentation to UHP management and its financial advisor, Société Générale. (https://www.unitedhealthproductsinc.com/press-releases/2018/11/28/united-health-products-united-health-engages-socit-gnrale-to-undertake-strategic-review).

About IQVIA

IQVIA, a publicly traded company whose stock is listed on the NYSE (IQV), is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 58,000 employees, IQVIA conducts operations in more than 100 countries. https://www.iqvia.com/

About United Health Products 

United Health Products develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all-natural product designed to absorb exudate/drainage from wounds to help control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.

For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact:
United Health Products, Inc.
877-358-3444

IR Contact:
PAN Consultants Ltd.
Philippe Niemetz
212-344-6464
p.niemetz@panconsultants.com